Price · as of 2025
$2.24
Market cap 561.56M
Valuation
| Metric | Value | Upside |
|---|---|---|
| IC Value | $0.59 | -74% |
| P/E | -1.33 | |
| P/B | 2.15 | |
| P/S | 5.07 | |
| EV/EBITDA | -1.73 | |
| PEG | -5.52 | |
| P/TBV | 2.42 |
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | IC | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $37.00 | $19.24 | |||
| 2019 | $8.25 | $21.02 | |||
| 2020 | $6.70 | $10.93 | |||
| 2021 | $3.98 | $11.79 | |||
| 2022 | $1.90 | $24.30 | |||
| 2023 | $5.71 | $15.12 | |||
| 2024 | $2.01 | $33.57 | |||
| 2025 | $1.44 | $41.84 |
Historic valuation ratios
Pick a category, then toggle metrics to compare.
Line items
Line items
Line items
About Autolus Therapeutics plc
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
- CEO
- Christian Martin Itin
- Employees
- 752
- Beta
- 2.03
Scroll horizontally for additional metrics. Ticker column stays fixed.
| Basic Info | IC Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | Value | Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| AUTL | Autolus Therapeutics plc | $2.24 | 561.56M | $41.85 | +1,768% | -1.33 | 2.15 | 5.07 | -1.73 | -5.52 | 2.42 | -27.83% | -372.45% | -381.40% | -94.98% | -451.87% | -41.92% | 1.97 | -7.66 | 5.94 | 5.13 | -0.99 | 24.14% | 646.68% | 28.87% | -81.07% | -3.86 | -513.82% | 0.00% | 0.00% | 0.00% | -1.54 | -1.40 | 5.74 | -3.45 |
| ADCT | ADC Therapeutics S.A. | $1.07 | 136.09M | $12.58 | +1,075% | -3.68 | -2.82 | 6.45 | -7.87 | — | -2.82 | 90.57% | -133.21% | -175.31% | 73.43% | 63.93% | -44.22% | -2.36 | -2.10 | 4.37 | 4.14 | -1.99 | -30.86% | 14.85% | 13.42% | -26.95% | -2.01 | 83.53% | 0.00% | 0.00% | 0.00% | -6.48 | -4.97 | 8.63 | -6.45 |
| ANNX | Annexon, Inc. | $5.37 | 879.83M | — | — | -4.25 | 4.15 | — | -3.26 | -13.00 | 4.15 | 0.00% | 0.00% | 0.00% | -81.90% | -4525.45% | -65.86% | 0.12 | — | 5.68 | 5.59 | 0.67 | 32.67% | — | 58.02% | -21.24% | -4.37 | -3899.90% | 0.21% | -0.90% | 13.35% | -3.08 | -3.57 | — | 1.65 |
| AURA | Aura Biosciences, Inc. | $7.18 | 460.95M | — | — | -3.38 | 2.62 | — | -2.21 | -590.64 | 2.62 | 0.00% | 0.00% | 0.00% | -73.52% | -759.69% | -60.35% | 0.13 | — | 8.15 | 7.85 | 0.40 | 0.57% | — | 5.10% | -23.77% | -4.61 | -573.78% | 0.00% | 0.00% | 8.15% | -2.05 | -2.72 | — | 1.38 |
| BNTC | Benitec Biopharma Inc. | $12.69 | 435.96M | — | — | -13.28 | 5.18 | — | -9.83 | — | 5.18 | 0.00% | 0.00% | 0.00% | -52.46% | 2846.97% | -49.96% | 0.01 | 12.71 | 54.67 | 54.26 | 2.34 | -60.82% | — | 20.55% | -4.69% | -13.09 | 1609.13% | 0.00% | 0.00% | 9.20% | -9.74 | -17.23 | — | 128.14 |
| LBRX | LB Pharmaceuticals Inc Co… | $45.03 | 1.29B | — | — | -25.77 | 2.16 | — | -14.38 | — | 2.16 | 0.00% | 0.00% | 0.00% | -24.38% | 55.69% | -14.55% | 0.01 | — | 41.44 | 39.67 | 9.91 | -94.39% | — | -34.49% | -5.43% | -4.73 | 64.59% | 0.00% | 0.00% | 35.00% | -11.77 | -10.15 | — | 33.78 |
| NMRA | Neumora Therapeutics, Inc… | $1.61 | 298.31M | — | — | -2.07 | 4.72 | — | -1.32 | — | 4.72 | 0.00% | 0.00% | 0.00% | -121.21% | 498.03% | -93.28% | 0.00 | -74.92 | 5.87 | 5.62 | 0.78 | -5.23% | — | 12.85% | -42.12% | -6.36 | 426.34% | 0.00% | 0.00% | 8.52% | -1.28 | -1.49 | — | -8.48 |
| QSI | Quantum-Si incorporated | $0.76 | 149.65M | $12.91 | +1,607% | -1.85 | 0.85 | 77.13 | -0.31 | — | 0.85 | 47.33% | -3996.72% | -4160.06% | -46.52% | -242.65% | -41.07% | 0.02 | — | 7.64 | 7.10 | 0.19 | -28.17% | -20.34% | 5.26% | -51.75% | -4.11 | -242.34% | 0.00% | 0.00% | 0.00% | -0.30 | -0.30 | 11.96 | -0.09 |
| RCKT | Rocket Pharmaceuticals, I… | $3.50 | 382.18M | — | — | -2.36 | 1.90 | — | -1.72 | — | 2.47 | 0.00% | 0.00% | 0.00% | -60.27% | -199.09% | -52.00% | 0.09 | -120.84 | 6.38 | 6.25 | 0.25 | -26.37% | — | -11.66% | -36.23% | -6.29 | -165.93% | 0.00% | 0.00% | 0.01% | -1.58 | -1.90 | — | -1.87 |
| SLDB | Solid Biosciences Inc. | $8.73 | 859.47M | — | — | -3.67 | 3.55 | — | -2.74 | — | 3.55 | 0.00% | 0.00% | 0.00% | -109.90% | -1387.90% | -82.78% | 0.12 | — | 6.14 | 5.61 | 0.22 | -34.97% | — | 56.40% | -24.61% | -4.67 | -1219.35% | 0.00% | 0.00% | 0.00% | -2.64 | -3.00 | — | -0.12 |
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.59 ÷ $2.24) − 1 = -73.66% (IC, example).